January 2, 2018 / 1:19 PM / Updated 9 minutes ago BRIEF-Avenue Says Dosed First Patient in Phase 3 Safety Trial of IV Tramadol Reuters Staff 1 Min Read 
Jan 2 (Reuters) - Avenue Therapeutics Inc: 
* AVENUE THERAPEUTICS ANNOUNCES DOSING OF FIRST PATIENT IN PHASE 3 SAFETY TRIAL OF INTRAVENOUS TRAMADOL FOR THE MANAGEMENT OF POSTOPERATIVE PAIN 
* AVENUE THERAPEUTICS INC - COMPANY EXPECTS TO INITIATE A SECOND PHASE 3 TRIAL IN PATIENTS FOLLOWING ABDOMINOPLASTY SURGERY IN Q3 OF 2018 
* AVENUE THERAPEUTICS- EVALUATING IV TRAMADOL IN PHASE 3 TRIAL IN PATIENTS FOLLOWING BUNIONECTOMY SURGERY, EXPECTS TO REPORT TOPLINE DATA IN Q2,2018 Source text for Eikon: Further company coverage: